Patients will be treated at less cost
New Delhi: Getting treatment for serious diseases is very expensive in India. Even for common diseases, if the patient is admitted to the hospital, a huge bill is generated. In such a situation, if someone has not taken health insurance, then hospital and doctor bills become a big problem for a common man.
But with the information given by the Union Health Ministry on Friday, even a common man will be able to get treatment for rare diseases easily and he will not have to spend crores of rupees for this. This facility can be easily achieved by spending a few lakhs.
What is the whole matter?
Union Health Ministry officials on Friday said that medicines for four rare diseases have become available at much cheaper rates as Indian pharmaceutical companies are now producing them by reducing dependence on expensive imported ‘formulations’. The price cut comes as the ministry has prioritized action related to ‘sickle cell anemia’ as well as 13 rare diseases.
Medicines for four of these diseases – tyrosinemia type 1, Gaucher disease, Wilson disease and Dravet-Lennox Gastaut syndrome as well as sickle cell anemia – have been approved and are being manufactured indigenously.
Approval process
Official sources said four more medicines for the three diseases – tablet Sapropterin for phenylketonuria, tablet Sodium Phenyl Butyrate and tablet Carglumic Acid for hyperammonemia and capsule Miglustat for Gaucher disease are in the process for approval and are expected to be available by April 2024. is likely to.
How much will the price of medicines reduce?
With these drugs being manufactured indigenously, the annual cost of Nitisinone capsules used in the treatment of tyrosinemia type 1 will be reduced to one hundredth of the price of the imported drug. A source in this regard said, “For example, while the annual cost of imported capsules comes to Rs 2.2 crore, domestically manufactured capsules will now be available for just Rs 2.5 lakh.”
Similarly, while imported Eliglustat capsules cost Rs 1.8-3.6 crore per annum, domestically manufactured capsules will now be available for only Rs 3-6 lakh per annum, the source said.
Imported Trientine capsules used in the treatment of Wilson’s disease cost Rs 2.2 crore per year, but with the drug being manufactured indigenously, it will be available for Rs 2.2 lakh.
The cost of imported cannabidiol (an oral drug) used in the treatment of Dravet-Lennox Gastaut syndrome ranges from Rs 7 lakh to Rs 34 lakh per year, but due to production in the country, it can be reduced to Rs 1 lakh per year. Will be available for Rs 5 lakh.
Commercial supply of hydroxyurea syrup, used in the treatment of sickle cell anemia, is likely to begin by March 2024 and the tentative price will be Rs 405 per bottle. Its price abroad is Rs 70,000 per 100 ml. All these medicines were not manufactured in the country till now. (Input: also from language)
Latest India News